Evidence map›Paper›PMID 35619925›Full record

ReviewFrontiers in oncology2022

Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities.

Laura Pohl, Jana Friedhoff, Christina Jurcic, Miriam Teroerde, Isabella Schindler, Konstantina Strepi, Felix Schneider, Adam Kaczorowski, Markus Hohenfellner, Anette Duensing and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Microphysiological systems as models for immunologically 'cold' tumors.Frontiers in cell and developmental biology · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Laura PohlMolecular Urooncology, Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.
Jana FriedhoffMolecular Urooncology, Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.
Christina JurcicMolecular Urooncology, Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.
Miriam TeroerdeMolecular Urooncology, Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.
Isabella SchindlerMolecular Urooncology, Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.
Konstantina StrepiMolecular Urooncology, Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.
Felix SchneiderMolecular Urooncology, Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.
Adam KaczorowskiMolecular Urooncology, Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.
Markus HohenfellnerDepartment of Urology, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany.
Anette DuensingDepartment of Urology, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany.
Stefan DuensingMolecular Urooncology, Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.
Heidelberg University · DEUniversity Hospital Heidelberg · DENational Center for Tumor Diseases · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is among the most lethal urological malignancies once metastatic. The introduction of immune checkpoint inhibitors has revolutionized the therapeutic landscape of metastatic RCC, nevertheless, a significant proportion of patients will experience disease progression. Novel treatment options are therefore still needed and

Indexed as

drug developmentintratumoral heterogeneity (ITH)patient-derived xenografts (PDX)preclinical studiesrenal cell carcinoma

Identifiers

PMID35619925
PMCPMC9128013
OpenAlexW4280547548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.